Related Experiment Videos
Hematopoetic stem cell transplantation for solid tumors in Europe
A Gratwohl1, H Baldomero, T Demirer
1Division of Hematology, Department of Internal Medicine, Kantonsspital Basel, Switzerland. hematology@uhbs.ch
Summary
Hematopoietic stem cell transplants (HSCT) for solid tumors saw significant changes in Europe between 1991-2002. Data reveal trends and provide objective insights for healthcare providers and patient counseling.
Area of Science:
- Hematology
- Oncology
- Transplantation Medicine
Background:
- Hematopoietic stem cell transplants (HSCT) are considered for solid tumors, but practice has varied.
- Limited controlled studies and differing opinions necessitate objective data on current HSCT use.
Purpose of the Study:
- To assess trends and rates of HSCT for solid tumors in Europe.
- To provide objective information on current HSCT practices for healthcare providers and patient counseling.
Main Methods:
- Analysis of 27,902 HSCT cases for solid tumors in Europe from 1991-2002.
- Data collected via the European Group for Blood and Marrow Transplantation (EBMT) activity survey.
- Assessment of transplant numbers, rates, and coefficient of variation.
Main Results:
- HSCT numbers surged from 536 (1991) to 4154 (1997), then declined to 1913 (2002).
- Breast cancer (48%) and germ cell cancer (12%) were leading indications; Ewing's sarcoma showed low variation (<56.5%) suggesting consensus.
- Allogeneic HSCT increased post-1997, primarily for renal cell carcinoma.
Conclusions:
- The study provides a comprehensive overview of HSCT practices for solid tumors across Europe.
- Objective data are presented to inform healthcare providers and aid in patient counseling regarding HSCT for solid tumors.